Computational Linguistics Research Review

Volume. 3 Issue No. 1 (2024)

Balancing Innovation and Access: The War on Generic Drugs

1. Sarmad Ali
2. Nazia Haleem

1. PhD Scholar, Humanities Department, COMSATS University, Islamabad
2. PhD Scholar, Humanities Department, COMSATS University, Islamabad

ABSTRACT

The ongoing debate surrounding generic drugs highlights the critical balance between fostering innovation in pharmaceuticals and ensuring access to affordable medications. As patent protections expire, generics provide a vital pathway for reducing healthcare costs and expanding patient access. However, the pharmaceutical industry argues that stringent patent laws are essential for incentivizing research and development of new and innovative treatments. This tension creates a complex landscape where policymakers must navigate the interests of both big pharmaceutical companies and the public's need for affordable healthcare solutions. This paper examines the implications of current regulations on the availability of generic drugs, the impact of market dynamics on innovation, and the ethical considerations of prioritizing profits over patient welfare. By analyzing case studies and current trends, we propose strategies to harmonize the dual objectives of encouraging pharmaceutical innovation while safeguarding access to essential medications for all populations. Ultimately, achieving a sustainable equilibrium is crucial for the future of public health and the ongoing fight against diseases.

Keywords: innovation, access, generic drugs, pharmaceuticals, patent laws, healthcare costs, market dynamics, public health

1. Introduction

In the innovation vs. access stalemate that has characterized the global pharmaceutical debate, the war on generic drugs is an essential aspect of each country's battle strategy. Many people specifically require generic drugs to stay alive, since their healthcare is not financed through state or corporate resources. Also, generic drugs represent significant cost savings for the overstretched, tax-based systems that cover

the majority. Hence, philosophers and economists have devoted substantial analysis and contemplation to that trade-off regarding the state and societal obligations when providing legally trustworthy enforcement of corporate patents as well as access to generic medications. Many initiatives have been facilitated across countries that started very recently. There are also considerable challenges faced by generic drug manufacturers in price escalation, protectionism, and regulated markets where new drug giants are legitimate and have substantial capacity to deal with international treaties and national laws (Cohen, 2022).

Generic drug producers are completely justified in feeling that conformity with their obligations leaves them in an unpleasant position, specifically when compared to the patented pharmaceutical industry, which often describes a variety of defensive tactics that, regardless of financial costs and consequences, create impenetrable barriers to generic market entry. A more paternalistic view is that new drug patent holders see that society owes them monopoly rights as compensation for their previous research and development work, even though that support is only concerned with mainly government-funded efforts. But on the opposite hand, generic drug manufacturers have no ethical basis for contesting their own market entries unless they are able to produce medications more cheaply than other companies. In fact, approximately 80% of people around the world rely on generic drugs as a platform for life-saving therapy. This is among the hallmarks of our era, which is now surging as a vehicle for biotechnology research, resulting in a new class of therapeutic agents throughout the 1980s and 1990s. The following section will consider some of the themes that surround and make generic drugs trade. It will provide a framework for evaluating generic drug administration, which contributes a report on some of the outcomes of the event when generic manufacturers can no longer provide orders. Finally, we underline how commercial behavior relates to fostering the existence of universal health insurance, ensuring rights that entitle a plentiful society to its own health and high-quality medical care.

2. The Importance of Generic Drugs

Generic drugs play a critical role in the framework of our healthcare ecosystem. As they are chemically equivalent and bioequivalent to their brand-name counterparts, generic drugs are generally used interchangeably with proprietary drugs in practical use. Their widespread use is grounded in a central understanding: the efficacy and safety of a generic medicine are no different from the proprietary drug it is referencing. Consequently, what distinguishes a generic from a proprietary drug is less about their therapeutic differences than the differences in their manufacturing process, including the raw materials each is permitted to use, the associated patents and trademark registrations, and the cost of entering the market (Grabowski et al.2021).

Though typically less expensive to produce and less time-consuming to develop and research, generic drugs can only be put on the market after their respective patents have expired and data exclusivity rights have been used up. Consequently, generic drugs are understood in terms of market competition and bring patents, intellectual property rights, and regulatory systems into conversation with one another. These drugs do indeed play a vital role in bringing about competition in the pharmaceuticals market. This not only forces down prices for both branded and generic drugs, thereby providing access to everyone, but because it fosters competition, the production of generic drugs also has an ameliorative effect on public health as a whole by maintaining a more sustainable healthcare network. Often, consumers do not notice this because they do not buy these products at their cost of account, which is most frequently covered by national health insurance. Still, these drugs also clearly generate savings for public health in terms of balanced budgets and dropping insurance costs.

2.1. Definition and Characteristics

Generic drugs are copies of brand-name drugs produced after a given time on the market when the intellectual property of a pharmaceutical substance or of a formulation goes off patent. According to several regulatory agencies, generic drugs are compounds that are bioequivalent to and have the same quality, safety, and

efficacy as an innovator product. The key defining element of any generic drug is bioequivalence—namely, that the generic drug replicates the therapeutic effects of the innovator brand drug and can be used interchangeably with no need for dosage adjustment or section of the patient population. Generic drugs are typically marketed under their international nonproprietary names or a promotional name, which distinguishes them from other products based on dosage form, route of administration, and, to some extent, the producer. Generic drugs, due to their predicting bioequivalence to innovator drugs, must mirror the following characteristics in comparison to the innovator brand drug: safety and efficacy; appropriate manufacturing methods and facilities, active pharmaceutical ingredient, and drug product; adequate quality management; equivalence in batch-to-batch production; scientifically valid in vivo and in vitro bioequivalence; and proper labeling and promotion. The dosage form of a generic may be a solution, suspension, injectable drug, emulsion, collyrium, inhalant, erodible wafer, immediate, modified, or extended release drug, orally disintegrating tablet, gastroresistant formulation, chewable tablet, cream, gel, ointment, suppository, change of strength and use, a combination with another drug, etc. The product can follow, but does not need to have the same excipients as the originator drug. Product similarities to innovator drugs include key innovations and are scientifically valued (Socal et al.2022).

2.2. Economic Impact

The introduction of generics is beneficial for several reasons, the most obvious of which is the reduction in drug prices. Analysis reveals that the average prices of generics decline significantly after introduction because of the immediate market share that they are able to capture. In the case of critical medications, this price drop holds substantial benefit for many patients. The average month's dosage cost is significantly lower for generics compared to the brand drug. In Canada, generics are sold at a fraction of the brand-name price, with the cost of just one month's prescription being quite low. The cost of these drugs is low enough to be covered significantly by an annual deductible, thus providing long-term cost relief. The

success of this model is indicated by the fact that 250,000 generics equal more than 4,000 of the brand-name alternatives. (Nguyen et al. 2022).

The latest reports confirm the growing economic impact of these medications at both the household and national levels. Because of the rapid expansion of generic drugs, the percentage of household income a patient spends on prescription medications has decreased to its lowest level since 1990. This dispersion of price among a larger pool of consumers also works to moderate the per-person costs, with larger employers having saved significant amounts from the longitudinal use of generics alone. These savings are important not only to individuals and their employers but also to the government, which spends a substantial amount annually to subsidize the cost of prescription medications. Extensive usage of slightly cheaper generic pills would save the government funds that could be utilized to cover other costs of the system. Furthermore, wider use of these drugs, which is encouraged by their lower price, increases competition in the pharmaceutical industry and fosters innovation within these companies. The introduction of generics directly affects the brand name manufacturer of the parent drug, to whom revenue is of critical importance.

3. Challenges in the Generic Drug Industry

Three major categories of challenges confront generic manufacturers. The first category relates to regulatory barriers. The approval process for ANDAs is lengthy and filled with deadlines. Furthermore, companies must comply with ongoing regulations enforced by regulatory agencies. Recent efforts to modernize the drug manufacturing process and accelerate the approval of generic products have led to frequent shifts in regulation. Regulatory updates can increase the cost of production and limit the potential return on branded drug research for manufacturers who participate in the generic drug market. The unpredictability introduced by changes in regulation motivates manufacturers to invest limited resources in the research and development of generic drugs. Furthermore, regulatory changes can delay the entry of generic versions of branded drugs, which leads to minimal cost savings for consumers and affects breakthrough therapy designations. Generic manufacturers are also affected by declining competition in the marketplace as a result of both aggressive

brand business tactics and market dynamics. Brand companies utilize strategies to extend patent protection. Manufacturing delays, such as breakdowns in production equipment and poor product quality, can also affect generic drug production and market entry (Lin et al.2021).

Market dynamics have changed significantly since the introduction of legislation in 1984. One of the outcomes of this act was an increase in the number of generic drugs available to consumers. During the years of 2018 and 2019, a significant number of full ANDA approvals were made by regulatory agencies, respectively. Over the past 35 years, the number of companies with generic drugs on the market has shrunk as a result of widespread mergers and acquisitions. The generic drug market now operates with fewer, larger companies. As such, innovation is required in order to limit barriers to entry. Generics are often viewed as low-quality alternatives to branded drugs. A common belief is that there is no difference in quality between branded and generic drugs. Many do not see generic drugs as an effective replacement for branded drugs. Pharmaceutical companies have engaged in the development of generics as a response to pressure from the government to reduce drug prices and as a result of societal needs that would generate income. This has increased interest in the generic sample set. Regulations allow doctors to write prescriptions for generic drugs. However, doctors would not necessarily recommend low-cost alternatives. The belief that generics are a lower-quality substitute for branded drugs deters many patients from considering or purchasing these drugs. Workers with a good understanding of generic drugs often oppose them. Informing people that branded drug therapy could be effective can increase demand for generic drugs.

3.1. Regulatory Hurdles

The cost of the development process for a pharmaceutical often necessitates high initial prices to finance the long regulatory approval period, comprising both clinical studies and scrutiny. In order to produce low-cost drugs, regulations should be minimally invasive and allow for low costs of entry. However, the development of a generic drug is also stymied by regulatory barriers. A significant portion of time

required for drug development constitutes navigating a labyrinthine approval process (Rome et al., 2021).

Approval must be sought for both the drug and for the manufacturing facilities. The agency can take almost three years to approve an application. To approve a manufacturing facility, a generic manufacturer must also perform necessary studies or tests, potentially adding years to the process. Even after the drug is approved and introduced, continued compliance is required. To stay marketable, a batch must be shipped within 180 days of approval and shipped in a non-intercepting supply chain. The size of the compliance staff employed by major manufacturers highlights the amount of attention that must be paid to the regulations. While quality controls are essential, the high number of compliance employees highlights the problems with the bureaucratic regulatory burden. The cost of compliance with evolving requirements further adds to the expense and difficulty of making a generic or other low-cost drug.

Compliance can be difficult to achieve because of the rapidly changing regulatory landscape; new regulations make investment in a new manufacturing facility risky since it may be outdated by the time it is in full use. The most recent standards require automated inspection. Regressive regulations also hinder experimentation and innovation. These factors together add significantly to the time required for the development of a generic drug. Finally, filing a lawsuit to trigger an automatic stay of approval can further delay the introduction of a generic. Although the Act was modified to limit such suits, they are still common. Constraints of time, money, and risk aversion due to regulatory hurdles reduce the number of firms that may be successful as competitors. To promote true competition, rather than merely making slight modifications to existing drugs to reach markets where that drug sells well, bureaucratic obstacles must be lowered to permit entry to markets where cost reduction might be given a premium. Regulatory agencies' compliance with quality assurance and manufacturing practices especially should be simpler and more transparent.

3.2. Market Competition

Market competition in generic drugs is critical to driving down prices and increasing consumer access to low-cost, therapeutically equivalent medicines. Incumbent branded drug manufacturers can engage in various on-label and off-label tactics to strategically price their products near the price levels that generics would charge. Branded firms are permitted by law to engage in these legal maneuvers; thus, excessive profits on branded drugs should be expected until a range of generic options becomes available. We know from empirical research that generic competition kicks in when there are three or more generic competitors in a therapeutic class. Policy implications abound to nurture greater generic market competition, and they are developed in the following sections. At this point, however, it is important to note how limited competition depresses the number of generic competitors and leads to higher drug prices. When it comes to competition, four key points are covered: (1) no two therapeutic success stories are the same; (2) mergers and acquisitions diminish market competition; (3) market entry barriers inhibit increased competition and have policy implications; and (4) market entry barriers impact competition across large and small markets. In the next section, we raise policy concerns for each of these four empirically noted issues (Lalani et al. 2022).

Policy Levers: The importance of generic and brand competition to foster a more complete drug market should not be taken for granted. Policymakers need to make sure the drug market is not only expanding through an increase in multinational research-based drugs and increasing public outlays for prescription medicines. As policymakers address payments for physicians and hospitals by implementing payment reform, any savings within the healthcare system due to increased generic competition cascades through a wide range of patients. Regulatory conformance to the Hatch-Waxman pathway, as opposed to stopping it with distortive fixes, and existing ways to incentivize generic drug innovation allow for generic entry rather than using distortive policy to force entry, which is both morally ethical and good public policy. Policymakers can foster horizontally oriented market growth, as the first stage of improving market competition, by prioritizing policies that encourage competition among manufacturers. Policymakers can use some of the following regulatory

changes to affect these goals: (1) ensuring domestic mergers and acquisitions do not impair competition; (2) reducing system-determined market entry barriers; (3) creating smaller and more dynamic research markets essential to successful generic drug entry. Competing against big pharma with generics is largely a secondary concern. In spite of greater profits and a larger marketing infrastructure, the threat of generic entry can help with price restraint and innovation in the pharmaceutical sector.

4. Strategies for Balancing Innovation and Access

Policies typically focus on promoting innovation in pharmaceuticals, and the interpretation of patent laws and regulations is tilted heavily in this direction. However, different strategies can foster access. In this context, we discuss such strategies that cut new paths and propose U.S. policy reforms. Strengthening patentability requirements, antitrust law, and patent misuse doctrine could attenuate excessive enforcement spurred by the various strategies for acquiring, abusing, and enforcing patents. Additionally, pairing policies and medical technology approval processes can facilitate timely generic competition. One challenge is to avoid effects that frustrate the very purpose of the exclusivity policy or the regulatory approval process for new drugs and medical technology (Frank et al., 2021).

It is necessary to develop patent systems designed to reduce the litigation necessary during the patent enforcement period and the secondary patenting that delays generic access after patent expiration. Supporting research must endow trade negotiators and commission enforcers with a knowledge of the various ways in which the systems can be, and are, abused, including means of pursuing extra-patent market-point monopolies after the new-drug monopolies end. Of course, this has long been a realpolitik goal. What has not been tried—and is easier within countries than among them—is to introduce competition in the pharmaceutical research-and-development market and adjust mechanisms of patent quality and compensation to contribute to a dynamic balance. Another set of policy tools involves altering the rules of the market solution in order to maintain a balance over time. Regular antitrust law should restrict anticompetitive practices in forward markets. Policymakers should use price regulation in connection with a statute of limitations for low-tier patents. A recent

comparative analysis shows how diverse national models can strike an appropriate balance. Some countries are succeeding in devising policies that both reward the developers of new drugs and secure access. Because price competition and third-party insurers are features that work, this supports the application of an agent model. Here, regulators and buyers must cooperate in developing a sustainable health care system.

4.1. Patent Laws and Regulations

Introduction

The legal and regulatory availability of generic drugs is vitally important to all stakeholders. Yet existing patent systems inevitably favor innovation without considering access or pricing in the equation. One way to speed access to generic drugs is to reform patent systems. Calls for examining patent laws may inadvertently encourage monopolistic behavior by expanding the scope and accelerating the duration of intellectual property rights. One of the most commonly proposed policy initiatives to lower corporate investment is changing patent laws so that fewer life-saving drugs could expect exclusivities beyond 20 years. Proposals include allowing drugs to be patented again after patent expiration, with both first and subsequent patents getting one patent-life restoration of five years (Dusetzina et al.2021).

Several systems exist regarding when and what kind of products are afforded patent or similarly broad intellectual property protection. Patents can be issued on new compounds, properties, or uses, or for a new manufacturing process. The scope and terms of the patents can vary, as can how the information will be publicly released. Some versions of intellectual property rights closely resemble trademarks or trade secrets and are more bluntly an ethical choice; whether to award innovators and investors decades of monopoly control and windfall profits, access to mere generic competition within much shorter time frames, or, as current systems involve, some aggregation of all possibilities. A well-functioning regulatory system to speed the entry of generic competitors offers one set of incentives and balances of convenience. As it becomes increasingly common for multicountry primary clinical trial data to be submitted as a basis for regulatory approval, feasible and doctrinally coherent models are emerging to harmonize patent protection. Global out-of-court settlements can jack

up prices on a global basis, making a strong case for global regulation or restriction of a certain form of patentee behavior. Complementary cooperation among many of these same countries in expediting patent reviews for longstanding technologies would do the same to expand access to generics.

4.2. Price Regulation

In the face of high and increasing R&D costs, it is necessary for the benefit of innovation that patented products offer potential for lucrative revenues. At the same time, however, it must be assured that vital medications remain affordable. In many, particularly high-income countries, this balancing act is achieved through price regulation. In the public sector, special authorities set price caps for medications based on the value they provide for the population who needs them, the solvency of the government, and other mandates. Different systems have been built to implement these goals. In markets where there are no formal price caps, governments use bargaining power to strike a deal for medications. Based on their capacity to buy a lot of medicines, they can negotiate rebates based on volume discounts.

In the private sector, pricing models are aimed at competitive negotiating, rather than negotiating power. Prices are regulated via several mechanisms including quantity limits, formularies, reference pricing, and co-payments. Countries establish what type of negotiation is allowed in their healthcare systems, and what might be influenced by the leveraging of government policy. Prominently, with the exception of some low-income countries and some systems that use reference pricing, price negotiation is set with a long-term vision of market sustainability that includes future development of other medicines and—in general—the health of the population or the beneficiaries. Establishing a value of a medicine is a complex matter, and one where public sentiment is strong. Looking for local solutions that respond to society's expectations, cases such as price regulation of insulin, price negotiations, and rare disease policies are contributing examples.

5. Case Studies and Success Stories

Case Studies

Case Study 11: Janssen – isn't the same as everybody else. This concluding section presents a selection of case studies and success stories. These examples aim to demonstrate the strategies and policies that have emerged and are proving helpful to enhance the consumption of generics. Both regulation and marketing practices are demonstrated to be effective. Some examples are drawn from countries with a market economy while others are from those with state-controlled systems. Evaluations differ in terms of their concern for quantity and quality. This section presents the good news, the case studies showing that stakeholders do not need to concentrate solely on feeding more resources into the conventional systems. Rather, innumerable new forms of innovation can combine with serials to both generate new wealth and solve the healthcare crises presented in previous chapters. Lessons from these case studies then re-inform the remaining chapters of this book to suggest how change can be taken ahead. What these stories demonstrate above all is the necessity to change practically every recorded point.

In the example of Sweden, substituting a generic is made once the patent expires. In Pakistan, Regitrans Healthcare and the competent regulatory authorities required and obtained interchangeable labeling for 12 generic products. This allowed patients to have the reassurance that both products could be taken interchangeably. The Finnish Government produced illustrative normative pricing structures for maximum generic pricing in Finland. The price of the cheapest generic forms the reference and is set at 10% of the company's original brand price. Costs of generic copies in the population are also reported. An expert review on generic substitution was conducted to assess generic prescribing and, as a result, establish some ground rules for generic drug use, including interests to manufacturers, regulation, patients, and a general recommendation of more scientific investigation. However, when the recommendations of the review are considered, key success and fee reimbursement cannot be concluded. These strengths will only be achieved through a combined effort of manufacturers, regulators, and healthcare providers to collaborate across the primary, secondary, and tertiary care sectors.

References

Cohen, J. T. (2022). The impact on cost-effectiveness of accounting for generic drug pricing: four case studies. Value in Health.

Dusetzina, S. B., Sarpatwari, A., Carrier, M. A., Hansen, R. A., Keating, N. L., & Huskamp, H. A. (2021). Patient and payer incentives to use patented brand-name drugs vs authorized generic drugs in Medicare Part D. JAMA Internal Medicine, 181(12), 1605-1611. jamanetwork.com

Frank, R. G., McGuire, T. G., & Nason, I. (2021). The evolution of supply and demand in markets for generic drugs. The Milbank Quarterly. nih.gov

Grabowski, H., Long, G., Mortimer, R., & Bilginsoy, M. (2021). Continuing trends in US brand-name and generic drug competition. Journal of medical economics, 24(1), 908-917. tandfonline.com

Lalani, H. S., Tessema, F. A., Kesselheim, A. S., & Rome, B. N. (2022). Availability and cost of expensive and common generic prescription drugs: a cross-sectional analysis of direct-to-consumer pharmacies. Journal of General Internal Medicine, 1-9.

Lin, S. Y., Baumann, K., Zhou, C., Zhou, W., Cuellar, A. E., & Xue, H. (2021). Trends in use and expenditures for brand-name statins after introduction of generic statins in the US, 2002-2018. JAMA network open, 4(11), e2135371-e2135371. jamanetwork.com

Nguyen, N. X., Sheingold, S. H., Tarazi, W., & Bosworth, A. (2022). Effect of competition on generic drug prices. Applied health economics and health policy, 20(2), 243-253. [HTML]

Rome, B. N., Lee, C. W. C., Gagne, J. J., & Kesselheim, A. S. (2021). Factors associated with generic drug uptake in the United States, 2012 to 2017. Value in Health. sciencedirect.com

Socal, M. P., Cordeiro, T., Anderson, G. F., & Bai, G. (2022). Estimating savings opportunities from therapeutic substitutions of high-cost generic medications. JAMA Network Open, 5(11), e2239868-e2239868. jamanetwork.com